Moving Beyond BRCA-Incorporating Molecular Assays into Ovarian Cancer Trials.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 32816948.
- Also identified by DOI 10.1158/1078-0432.CCR-20-2429.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
PrOTYPE is a locked down assay validated to Institute of Medicine standards, using NanoString technology to classify high-grade serous ovarian cancer into four defined subgroups. Future directions will include prospective-retrospective analysis and prospective clinical validation to define the predictive role of this assay and its role in influencing treatment decisions.<i>See related article by Talhouk et al., p. 5411</i>.
Medical subject headings
- Ovarian Neoplasms